Articles related to RESEARCH & CLINICAL TRIALS

A single 25-mg dose of synthetic psilocybin with structured psychological support produced rapid, large-magnitude reductions in suicidal ideation through 12 weeks in 20 treatment-resistant adults with major depressive disorder, with two participants experiencing worsening ideation.

Perioperative apalutamide plus ADT, six months before and after radical prostatectomy, achieved a ninefold improvement in major pathologic response and a 20% reduction in metastasis-free survival events versus placebo plus ADT in patients with high-risk localized or locally advanced prostate cancer in a phase 3 trial.

Talazoparib plus enzalutamide reduced the risk of radiographic progression or death by 52% versus enzalutamide alone in patients with metastatic castration-sensitive prostate cancer harboring homologous recombination repair gene alterations, with a 3-year rPFS rate of 77% versus 56% in a 599-patient phase 3 trial.

A two-sample analysis of GWAS data identified genetically predicted associations between six commonly prescribed medications and increased erectile dysfunction risk, while aspirin did not reach statistical significance after SNP exclusions.

Tafasitamab plus lenalidomide added to R-CHOP reduced the risk of progression or death by 25% compared with R-CHOP alone in previously untreated high-risk DLBCL and HGBL in a 899-patient phase 3 trial, with overall survival data not yet mature.

Neoadjuvant apalutamide plus abiraterone and ADT before radical prostatectomy was associated with improved 12-month potency recovery and lower positive surgical margin rates compared with surgery alone in a small phase 2 trial of men with high-risk localized prostate cancer.